News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ImmunoGen Inc.
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
December 10, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
November 02, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
October 19, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
September 28, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
July 17, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
June 09, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
June 04, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
May 04, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
May 03, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
April 13, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
February 15, 2023
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
November 14, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
October 20, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results
July 14, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates
June 13, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
April 21, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and 2021 Financial Results
February 25, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
February 15, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
February 10, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
January 31, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2022
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
December 02, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Proposed Public Offering of Common Stock
November 30, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
November 30, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
November 17, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
November 16, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
October 29, 2021
From
ImmunoGen Inc.
Via
Business Wire
Tickers
IMGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.